Editorial companion

What stands out

Beijing released a five-year plan for the pharmaceutical sector, and Citigroup said it broadly supports domestic innovators, biotech companies, artificial intelligence (AI), which speeds up drug discovery, and makers of high-end medical devices. That policy-and-banker endorsement is the clearest reason Chinese pharma stocks moved together today: a government roadmap plus a major bank endorsement can shift capital allocation and produce sectorwide momentum.